Showing 81 - 100 results of 34,708 for search '(( 2 w decrease ) OR ( 50 ((((nn decrease) OR (teer decrease))) OR (a decrease)) ))', query time: 1.11s Refine Results
  1. 81
  2. 82
  3. 83

    Exercise testing criteria to diagnose lower extremity peripheral artery disease assessed by computed-tomography angiography - Fig 2 by O. Stivalet (6890189)

    Published 2019
    “…<p><b>ROC curves of the different tests to diagnose arterial stenosis ≥ 50% in the overall population (<i>n = 126 limbs</i>)</b> (A) and in the population with an ABI > 0.91 (<i>n = 60 limbs</i>) (B). …”
  4. 84
  5. 85
  6. 86
  7. 87

    Junction assembly in 3D cell cultures is severely impaired for W2A mutant. by Stefanie Bunse (491659)

    Published 2013
    “…At 3 h (inset) the roundness of all mutants was significantly lower than WT. W2A and V81D/V174D had significantly lower roundness even after 20 h and 48 h of spheroid formation (two-tailed unpaired, t-test, P < 0.05). n(WT) = 9, n(W2A) = 9, n(R14E) = 8, n(V81D/V174D) = 8 spheroids. …”
  8. 88
  9. 89
  10. 90

    Fenretinide decreases levels of PAX3/FOXO1 and its target genes in aRMS cell lines. by David Herrero Martín (286820)

    Published 2013
    “…D) Fenretinide did not decrease mRNA levels of FOXO1 in aRMS cells. qRT–PCR was carried out after treatment with an IC<sub>50</sub> concentration of fenretinide during different time points (24–48–72 hours). …”
  11. 91

    Supplementary Material for: Use of the Myocardial Performance Index in Decreased Fetal Movement Assessment: A Case-Control Study by Ho D. (4108837)

    Published 2017
    “…<p><b><i>Objectives:</i></b> To determine whether there are any fetal cardiac function changes, as measured by the myocardial performance index (MPI), in pregnancies complicated by decreased fetal movement (DFM). <b><i>Methods:</i></b> We performed a prospective cross-sectional case-control study of 50 DFM and 50 uncomplicated third-trimester pregnancies matched within 2 gestational weeks. …”
  12. 92
  13. 93
  14. 94
  15. 95

    Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

    Published 2016
    “…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”
  16. 96
  17. 97
  18. 98
  19. 99
  20. 100